Purpose: The purpose of this review article is to describe the recent data supporting the use of epidermal growth factor receptor (EGFR) receptor tyrosine kinase inhibitors (TKIs) in the first-line setting of EGFR mutation-positive non-small cell lung cancer (NSCLC).
Summary: EGFR receptor TKIs were originally developed in unselected NSCLC patients and demonstrated modest clinical benefit compared to placebo. With the discovery of improved benefits in the approximately 16% of NSCLC patients with an EGFR mutation, trials in selected populations were undertaken, demonstrating comparable efficacy to standard chemotherapy with an improved toxicity profile. The most common toxicity is rash, sometimes requiring dose adjustment and discontinuation and the most serious toxicity is interstitial lung disease, which occurs in about 1% of patients treated with EGFR receptor TKIs and is fatal in 30% who develop this toxicity.
Conclusion: The EGFR receptor TKIs are an effective therapy in EGFR-mutated NSCLC and are recommended as first-line therapy for those with advanced or metastatic disease.
NCCN. National Comprehensive Cancer Network clinical practice guidelines in oncology: non-small cell lung cancer, Version 2.2010, 2010.
4.
MokTSWUYThongprasertS. Gefitinib or caboplatin-paclitaxel in pulmonary adenocarcinoma. NEngl J Med2009; 361(10): 947–957.
5.
WangYMinoshimaSShimizuN. Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique. J Hum Genet1993; 38(4): 399–406.
RosellRMoranTQueraltC. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med2009; 361(10): 958–967.
8.
InoueAKobayashiKUsuiK. First-line gefitinib for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol2009; 27(9): 1394–1400.
9.
ShepherdFPereiraJRCiuleanuT. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med2005; 353(2): 123–132.
10.
TsaoMSakuradaACutzJ. Erlotinib in lung cancer-molecular and clinical predictors of outcome. NEngl J Med2005; 353(2): 133–144.
11.
CappuzzoFCiuleanuTStelmakhL. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol2010; 11(6): 521–529.
12.
RosellRMoranTQueraltC. Spanish lung cancer group, screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med2009; 361(10): 958–967.
13.
MaemondoMInoueAKobayashiK. North-east Japan study group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med2010; 362(25): 2380–2388.
14.
AzzoliCBakerSTeminS. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol2009; 27(36): 6251–6266.
15.
TsimboukisSMerikasIKarapanagiotouEMSaifMWSyrigosKN. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer2009; 10(2): 106–111.
16.
LynchTJKimESEabyBGareyJWestDLacoutureME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist2007; 12(5): 610–621.
17.
ThatcherNNicolsonMGrovesR. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the U.K. Oncologist2009; 14(8): 840–847.
18.
JiaYLacoutureMESuXWuS. Risk of skin rash associated with Erlotinib in cancer patients: a meta-analysis. J Support Oncol2009; 7(6): 211–217.
19.
HottaKKiuraKTakigawaN. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer. J Thorac Oncol2010; 5(2): 179–184.
20.
RakhitAPantzeMFettnerS. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol2008; 64(1): 31–41.
21.
LingJFettnerSLumBRiekMRakhitA. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs2008; 19(2): 209–216.
22.
Prescribing information. Tarceva (erlotinib). Melville, NY: OSI Pharmaceuticals, Inc., 2008.
